![]() All symptoms were recorded using an Interactive Voice Response system. ![]() Within one hour of awakening the following morning, subjects completed night-time symptom relief and sleep satisfaction assessments. On the evening of enrollment, subjects rated baseline symptoms, ingested the assigned study product and completed symptom-relief assessments at 3 hours post-dosing. Subjects were randomized into either Group T (test syrup) or Group P (placebo syrup). At enrollment, eligible subjects had to have at least moderate nasal congestion and a runny nose, at least mild cough and at least mild pain with one or more of the following: sore throat, sore chest, headache or body pain/aches. This was a randomized, double-blind, placebo-controlled, multi-center, parallel design study. The aim of this study was to evaluate the efficacy of a single night-time dose of a syrup containing paracetamol, dextromethorphan hydrobromide, doxylamine succinate and ephedrine sulfate in subjects with multiple cold symptoms.Ī syrup containing 15 mg dextromethorphan hydrobromide, 7.5 mg doxylamine succinate, 600 mg paracetamol and 8 mg ephedrine sulfate (Wick MediNait produced by WICK Pharma, Germany, a subsidiary of Procter & Gamble GmbH test syrup) or placebo (placebo syrup) for oral administration.
0 Comments
Leave a Reply. |